The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

NCT02312206 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

260

Enrollment

INDUSTRY

Sponsor class

Stopped The VITAL study was terminated due to futility analysis

Conditions

Primary Systemic (AL) Amyloidosis

Interventions

DRUG: NEOD001
OTHER: Placebo

Sponsor

Prothena Biosciences Ltd.